NCT03610581 - Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 27, 2018

Primary Completion Date

October 15, 2020

Study Completion Date

October 15, 2020

Conditions

Human Papillomavirus Infections

Interventions

BIOLOGICAL

Ad26.HPV16

Participants will receive Ad26.HPV16 as a solution for intramuscular injection.

BIOLOGICAL

Ad26.HPV18

Participants will receive Ad26.HPV18 as a solution for intramuscular injection.

BIOLOGICAL

MVA.HPV16/18

Participants will receive MVA.HPV16/18 as a solution for intramuscular injection.

BIOLOGICAL

Placebo

Participants will receive matched placebo as a solution for intramuscular injection.

Trial Locations (12)

3000

UZ Leuven, Leuven

10032

Columbia University Medical Center, New York

33014

San Marcus Research Clinic, Inc., Miami Lakes

33166

Doral Medical Research, Doral

33174

Florida Research Center Inc., Miami

33912

Clinical Physiology Associates, Fort Myers

37920

VGR & NOCCR - Knoxville, Knoxville

52242

University of Iowa Hospital, Iowa City

66160

University of Kansas Medical Center, Kansas City

67114

Heartland Research Associates, LLC, Newton

68701

Meridian Clinical Research, LLC, Norfolk

70006

Medpharmics, LLC, Metairie